ACA
PTCT icon

Avoro Capital Advisors’s PTC Therapeutics PTCT Stock Holding History

Avoro Capital Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-685,000
Closed -$52M – 36
2025
Q4 		$52M Buy
+685,000
New +$49.8M 0.51% 23
2020
Q3 		– Sell
-324,750
Closed -$16.5M – 51
2020
Q2 		$16.5M Sell
324,750
-875,250
-73% -$43M 0.33% 38
2020
Q1 		$53.5M Buy
+1,200,000
New +$60.4M 1.81% 18
2019
Q4 		– Sell
-684,000
Closed -$23.1M – 35
2019
Q3 		$23.1M Hold
684,000
– – 0.97% 23
2019
Q2 		$30.8M Buy
+684,000
New +$27M 1.06% 22
2019
Q1 		– Sell
-380,000
Closed -$13M – 34
2018
Q4 		$13M Sell
380,000
-304,000
-44% -$10.9M 0.78% 23
2018
Q3 		$32.1M Sell
684,000
-1,610,877
-70% -$66.7M 1.48% 18
2018
Q2 		$77.4M Buy
+2,294,877
New +$71.6M 2.98% 11
2017
Q3 		– Sell
-120,000
Closed -$2.2M – 47
2017
Q2 		$2.2M Buy
+120,000
New +$1.62M 0.28% 34

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Avoro Capital Advisors's PTCT Position: Q1 2026 in Review

Avoro Capital Advisors sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 685,000 shares — an estimated $52M sold.

Avoro Capital Advisors first reported a position in PTCT in Q2 2017 and held it in 9 quarters. The position peaked at $77.4M in Q2 2018. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Avoro Capital Advisors reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Avoro Capital Advisors sold 685,000 PTC Therapeutics shares in Q1 2026, an estimated $52M.
  • Avoro Capital Advisors first reported a position in PTC Therapeutics in Q2 2017 and held it in 9 quarters.
  • Avoro Capital Advisors's PTC Therapeutics position peaked at $77.4M in Q2 2018.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Avoro Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.